PET in the follow-up of differentiated thyroid cancer

British Journal of Radiology

Volumn 76, Issue 910, 2003, Pages 690-695

  Khan, N ^a   Oriuchi, N ^a   Higuchi, T ^a   Zhang, H ^a   Endo, K ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROTROPIN;

CANCER CELL; CANCER RECURRENCE; CANCER TISSUE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FOLLOW UP; HORMONAL REGULATION; HUMAN; IODINE 131 UPTAKE TEST; METASTASIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 0142060321     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/31538331     Document Type: Review

References (56)

1. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: A commentary on the second edition. Cancer 1989;63:908.
2. Sanders LE, Cady B. Differentiated thyroid cancer: Reexamination of risk groups and outcome of treatment. Arch Surg 1998;133:419-25.
3. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical prospective and current status. J Endocrinol Invest 1999;22(11 Suppl):3-7.
4. Schlumberger MJ. Papillary and follicular carcinoma. N Engl J Med 1998;338:297-306.
5. Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY. Use of radioactive iodine for thyroid remnant ablation in well differentiated thyroid carcinoma to replace the thyroid reoperation. Am J Clin Oncol 1998;21:77-81.
6. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 1988;29:1790-4.
7. Black EG, Cassoni A, Gimlette TM, Harmer CL, et al. Serum thyroglobulin in thyroid cancer. Lancet 1981;2:443-5.
8. Grant S, Luttrell B, Reeve T, et al. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer 1984;54:1625-8.
9. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996;25:93-113.
10. Nakada K, Katoh C, Kanegae E, et al. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med 1998;39:807-10.
11. Yen T-C, Lin H-D, Lee C-H, Chang S-L, Yeh S-H. The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: A comparison with iodine-131 and thallium-201. Eur J Nucl Med 1994;21:980-3.
12. Lind P, Gallowitsch HJ, Langsteger W, et al. Technetium-99m-tetrofosmin whole body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997;38:348-52.
13. Tenenbaum F, Lumbroso J, Schlumberger M, Caillou B, Fragu P, Parmentier C. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1995;36:807-810.
14. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma; Contribution for patients with negative radioiodine scans. J Clin Endocrinol Metab 1996;81:2541-4.
15. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-48.
16. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 1996;37:1428-36.
17. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999;40:1706-15.
18. Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward PH. Positron emission tomography: A new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-8.
19. Schirrmeister H, Buck A, Guhlmann A, Reske SN. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid 2001;11:677-83.
20. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
21. Erdi YE, Macapinlac HA, Larson SM, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Pos Imaging 1999;2:41-6.
22. Patton JA, Turkington TG. Coincidence imaging with a dual-head scintillation camera. J Nucl Med 1999;40:432-41.
23. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Routsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study. J Nucl Med 1993;34:1-6.
24. Cook GJR, Maisy MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363-78.
25. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-84.
26. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-9.
27. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910-4.
28. Feine U, Leitzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schuenburg W. Fluorine-18-FDG and Iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
29. Feine U. Fluoro-18-deoxyglucose positron emission tomography in differentiated thyroid carcinoma. Eur J Endocrinol 1998;138:492-6.
30. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-9.
31. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8.
32. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schafers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998;383:160-3.
33. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med 1999;40:1623-9.
34. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
35. 131I whole-body scan. J Nucl Med 1999;40:986-92.
36. Plotkin M, Hautzel H, Krause BJ, et al. Implication of 2-18fluoro-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid 2002;12:155-61.
37. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative I-131 scan. J Nucl Med 2001;42:71-6.
38. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797-804.
39. 201T1 in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001;42:414-9.
40. 131I]-iodine whole-body scans. J Clin Endocrinol Metab 1999;84:2291-302.
41. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-13.
42. Muros MA, Llamas-Elvire JM, Ramirez-Navarro A, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulun levels. Am J Surg 2000;179:457-61.
43. Yeo JS, Chung JK, So Y, et al. F-18-fluorodeoxyglucose positron emission tomography as presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001;23:94-103.
44. Frilling A, Gorges R, Tecklenborg K, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000;128:1067-74.
45. 18F] fluorodeoxyglucose positron emission tomography in patients with radioiodine negative recurrent well differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
46. Alnafisi NS, Driedger AA, Coates G, Moote DG, Raphael SJ. FDG PET of recurrent or metastatic I-131 negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010-15.
47. Helal BO, Merlet P, Toubert M-E, et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy. J Nucl Med 2001;42:1464-9.
48. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-96.
49. Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinol 1987;120:2576-81.
50. Hosaka Y, Tawata M, Kurihara A, Endo T, Onaya T. The regulation of two distinct glucose transporter (GLUT1 and GLUT 4) gene expressions in cultured rat thyroid cells by thyrotropin. Endocrinol 1992;131:159-65.
51. Sisson JC, Ackerman RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77:1090-4.
52. Moog F, Linke R, Tiling R, et al. The influence of TSH levels on the uptake of F-18-FDG in metastatic thyroid cancer [abstract]. Eur J Nucl Med 1999;26(Suppl):1014p.
53. Grunwald F, Menzel C, Bender H, et al. Comparison of FDG PET, I-131 and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
54. Moog F, Linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-95.
55. Van Tol KM, Jager PL, Piers DA, et al. Better yield of 18Fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12:381-7.
56. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002;29:641-7.